Literature DB >> 19948412

Predictors of survival in patients with locally advanced thymoma and thymic carcinoma (Masaoka stages III and IVa).

Giuseppe Cardillo1, Francesco Carleo, Roberto Giunti, Michele Giovanni Lopergolo, Lorenzo Salvadori, Alessia Raffaella De Massimi, Lea Petrella, Massimo Martelli.   

Abstract

OBJECTIVE: We sought to evaluate factors influencing long-term survival of patients with locally advanced thymoma/thymic carcinoma (Masaoka stages III and IVa) treated by immediate surgery or induction therapy plus surgery.
METHODS: From January 1991 to April 2007, we surgically treated 61 patients with locally advanced thymoma/thymic carcinoma (Masaoka stages III and IVa). Staging included total body computed tomography (CT) scan in all patients, and chest magnetic resonance imaging (MRI) in 27 selected patients. All patients had histological confirmation before surgery. Thirty-one patients (group A) underwent induction chemotherapy followed by surgery. Thirty patients (group B) underwent immediate surgery. Thirty-four patients (group A: 13; group B: 17) received postoperative radiation therapy.
RESULTS: No intra-operative mortality was reported. World Health Organization (WHO) histological classification included 19 AB, four B1, seven B2 and 13 B3 thymomas and 18 thymic carcinomas. Thirty-four patients were Masaoka stage III (group A: 18; group B: 16) and 27 patients were stage IVa (group A: 13; group B: 14). After a median follow-up of 77 months, six patients of group A and seven patients of group B died of disease. The overall 10-year survival rate was 50.6%. The 10-year survival rate was 57.9% in group A and 38.1% in group B (p=0.03). Multivariate analysis showed complete resection (p=0.02), Masaoka stage (III vs IVa) (p=0.02), induction chemotherapy (group A vs group B) (p=0.003) and histological WHO subtype (AB vs B1, B2 and B3) (p=0.01) to be statistically significant independent predictors of survival. Sex, age and adjuvant radiation therapy showed no statistically significant difference.
CONCLUSIONS: Complete resection, Masaoka stage, induction chemotherapy and histological WHO classification showed to be independent predictors of survival in locally advanced thymoma/thymic carcinoma. Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19948412     DOI: 10.1016/j.ejcts.2009.11.001

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  29 in total

1.  Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy?

Authors:  Sukhmani K Padda; Marlies Keijzers; Heather A Wakelee
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

2.  Radiographic Predictors of Resectability in Thymic Carcinoma.

Authors:  Sara A Hayes; James Huang; Jennifer Golia Pernicka; Jane Cunningham; Junting Zheng; Chaya S Moskowitz; Michelle S Ginsberg
Journal:  Ann Thorac Surg       Date:  2018-03-11       Impact factor: 4.330

3.  Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database.

Authors:  Enrico Ruffini; Frank Detterbeck; Dirk Van Raemdonck; Gaetano Rocco; Pascal Thomas; Walter Weder; Alessandro Brunelli; Andrea Evangelista; Federico Venuta
Journal:  Eur J Cardiothorac Surg       Date:  2014-01-30       Impact factor: 4.191

4.  Quantitative assessment of target delineation variability for thymic cancers: Agreement evaluation of a prospective segmentation challenge.

Authors:  Emma Holliday; Clifton D Fuller; Jayashree Kalpathy-Cramer; Daniel Gomez; Andreas Rimner; Ying Li; Suresh Senan; Lynn D Wilson; Jehee Choi; Ritsuko Komaki; Charles R Thomas
Journal:  J Radiat Oncol       Date:  2015-11-03

5.  Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group.

Authors:  Pier Luigi Filosso; Xiaopan Yao; Enrico Ruffini; Usman Ahmad; Alberto Antonicelli; James Huang; Francesco Guerrera; Federico Venuta; Dirk van Raemdonck; William Travis; Marco Lucchi; Andreas Rimner; Pascal Thomas; Walter Weder; Gaetano Rocco; Frank Detterbeck; Robert Korst
Journal:  Eur J Cardiothorac Surg       Date:  2016-03-31       Impact factor: 4.191

6.  Pretreatment biopsy for histological diagnosis and induction therapy in thymic tumors.

Authors:  Jie Yue; Zhitao Gu; Zhentao Yu; Hongdian Zhang; Zhao Ma; Yuan Liu; Wentao Fang
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

7.  Preoperative induction therapy for locally advanced thymic tumors: a retrospective analysis using the ChART database.

Authors:  Yucheng Wei; Zhitao Gu; Yi Shen; Jianhua Fu; Liejie Tan; Peng Zhang; Yongtao Han; Chun Chen; Renquan Zhang; Yin Li; Keneng Chen; Hezhong Chen; Yongyu Liu; Youbing Cui; Yun Wang; Liewen Pang; Zhentao Yu; Xinming Zhou; Yangchun Liu; Yuan Liu; Wentao Fang
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

8.  The comparison of predictive factors regarding prognoses and invasion of thymic neuroendocrine tumors preoperatively and postoperatively.

Authors:  Dongliang Bian; Mengfan Qi; Junjie Hu; Ye Ning; Feng Zhou; Ke Fei; Peng Zhang
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

9.  Elevated pretreatment serum lactate dehydrogenase level predicts inferior overall survival and disease-free survival after resection of thymic carcinoma.

Authors:  Qianwen Liu; Xiayu Fu; Xiaodong Su; Xin Wang; Yijun Zhang; Hong Yang; Yi Hu; Jing Wen; Jianhua Fu
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

10.  Is Hyperthermic Intrathoracic Chemotherapy (HITHOC) Safe and Efficacious in Masaoka-Koga Stage-IVA Thymoma? A Pilot Study.

Authors:  Arvind Kumar; Mohan Venkatesh Pulle; Belal Bin Asaf; Harsh Vardhan Puri; Aparna Kumar; Sukhram Bishnoi
Journal:  Indian J Surg Oncol       Date:  2021-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.